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Aims: Glucagon-like peptide-1 (GLP-1) receptor agonists are appealing as glucose-lowering ther-
apy for individuals with type 2 diabetes mellitus (T2DM) as they also reduce body weight and
are associated with low rates of hypoglycaemia. This analysis assessed the long-term cost-
effectiveness of semaglutide 0.5 and 1 mg vs dulaglutide 1.5 mg (two once-weekly GLP-1
receptor agonists) from a UK healthcare payer perspective, based on the head-to-head SUS-
TAIN 7 trial, to inform healthcare decision making.
Materials and Methods: Long-term outcomes were projected using the IQVIA CORE Diabetes
Model (version 9.0). Baseline cohort characteristics, changes in physiological parameters and
adverse event rates were derived from the 40-week SUSTAIN 7 trial. Costs to a healthcare
payer were assessed, and these captured pharmacy costs and costs of complications. Utilities
were taken from published sources.
Results: Once-weekly semaglutide 0.5 and 1 mg were associated with improvements in quality-
adjusted life expectancy of 0.04 and 0.10 quality-adjusted life years, respectively, compared
with dulaglutide 1.5 mg. Clinical benefits were achieved at reduced costs, with lifetime cost sav-
ings of GBP 35 with once-weekly semaglutide 0.5 mg and GBP 106 with the once-weekly sema-
glutide 1 mg, resulting from fewer diabetes-related complications due to better glycaemic
control. Therefore, both doses of once-weekly semaglutide were considered dominant vs dula-
glutide 1.5 mg (improving outcomes and reducing costs).
Conclusions: Compared with treatment with dulaglutide, once-weekly semaglutide represents a
cost-effective option for treating individuals in the UK with T2DM who are not achieving gly-
caemic control with metformin, projected to both improve clinical outcomes and reduce costs.
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1 | INTRODUCTION
Improving glycaemic control remains a key focus of care for individ-
uals with type 2 diabetes mellitus (T2DM), and landmark studies show
that good glycaemic control can reduce the incidence of diabetes-
related complications.1–5 Guidelines from the National Institute for
Health and Care Excellence (NICE) recommend a glycated haemoglobin
(HbA1c) target of 6.5% (48 mmol/mol) for individuals with T2DM who
are managed with lifestyle modifications and a single drug, and a target
of 7% (53 mmol/mol) for individuals with T2DM who are not ade-
quately controlled by a single glucose-lowering drug.6 In addition, there
is substantial evidence that multifactorial care, targeting not only gly-
caemic control but also blood pressure, serum lipids, body weight and
hypoglycaemia risk, is associated with a reduced risk of
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complications.7–10 Consequently, NICE guidelines recommend a weight
loss target of 5% to 10% of body weight and a blood pressure target of
below 140/80 mmHg, in conjunction with glycaemic control targets.6
A significant number of individuals with T2DM in the UK are not
reaching recommended targets. Data from the National Diabetes
Audit show that during 2016–2017, one third of the individuals with
T2DM in England and Wales had an HbA1c value above 7.5%
(58 mmol/mol), and one quarter had blood pressure above
140/80 mmHg.11 In Scotland, over 40% of the individuals with T2DM
had an HbA1c value above 7.5% (58 mmol/mol) and one quarter had
systolic blood pressure greater than 140 mmHg in 2016.12 Therefore,
there is a significant need to improve care for individuals with T2DM
in the UK. Bringing a greater proportion of individuals with T2DM to
glycaemic control and multifactorial treatment targets can improve
long-term outcomes for patients and reduce the costs of treating
diabetes-related complications for healthcare providers and UK soci-
ety as a whole. This is key in optimizing the use of the limited
resources within the National Health Service (NHS).
In addition to its impact on glycaemic control, glucagon-like pep-
tide 1 (GLP-1) receptor agonist therapy is associated with weight loss,
as opposed to other treatment options, such as sulfonylurea and thia-
zolidinediones which are associated with weight gain, or dipeptidyl
peptidase-4 (DPP-4) inhibitors which are weight neutral.13 Sodium-
glucose co-transporter-2 (SGLT-2) inhibitors are the only other
second-line treatment option associated with weight loss, but these
are less efficacious than GLP-1 receptor agonists in terms of glucose-
lowering.14,15 Once-weekly semaglutide, a novel GLP-1 receptor ana-
logue, has been approved for use in Europe.16 Other GLP-1 receptor
agonists that are approved for once-weekly administration include
dulaglutide and exenatide extended-release.17,18 The SUSTAIN clinical
trial programme found that once-weekly semaglutide was more effica-
cious in terms of both HbA1c and weight reduction than exenatide
extended-release and dulaglutide, with a similar side-effect profile, in
head-to-head studies.19,20 Additionally, a network meta-analysis
(NMA) has shown that once-weekly semaglutide is more efficacious
than other GLP-1 receptor agonists.21
The SUSTAIN 7 clinical trial assessed the efficacy and safety of
once-weekly semaglutide vs dulaglutide.20 The SUSTAIN 7 trial was a
40-week, randomized, open-label trial comparing once-weekly sema-
glutide 0.5 mg with dulaglutide 0.75 mg, and comparing once-weekly
semaglutide 1 mg with dulaglutide 1.5 mg. The study included individ-
uals with T2DM who were not achieving glycaemic control, defined as
HbA1c 7.0% to 10.5% (53-91 mmol/mol) with metformin. Pre-
specified statistical analyses indicated that once-weekly semaglutide
1 mg was associated with significantly greater reductions in HbA1c
(−1.8% vs −1.4% [−19.4 vs −14.9 mmol/mol]; P < 0.001) and body
weight (−6.5 kg vs −3.0 kg; P < 0.001) vs dulaglutide 1.5 mg.20 Post-
hoc analysis has shown that both once-weekly semaglutide and dula-
glutide were associated with greater weight reduction in patients with
a higher body mass index (BMI) at baseline, and once-weekly semaglu-
tide was associated with greater reductions than dulaglutide across all
baseline BMI sub-groups.22 As dulaglutide 0.75 mg is not considered a
maintenance dose in dual therapy by the European Medicines Agency
(EMA), it is not included in the present analysis.17
The aim of the present study was to assess the long-term cost-
effectiveness of both doses of once-weekly semaglutide vs dulaglu-
tide 1.5 mg for treatment of individuals with T2DM who are not
achieving glycaemic control with metformin, based on SUSTAIN 7 clin-
ical trial data from the perspective of a UK healthcare payer.
2 | MATERIALS AND METHODS
2.1 | IQVIA CORE Diabetes Model
A cost-effectiveness analysis was performed using the IQVIA CORE
Diabetes Model (CDM), the architecture and capabilities of which
have been previously published.23 Projected long-term outcomes have
been validated against real-life data in 2004 and more recently in
2014.24,25 Model outputs include complication rates and time to onset
of complications, life expectancy, quality-adjusted life expectancy
expressed in quality-adjusted life years (QALYs), direct costs and
incremental cost-effectiveness ratios (ICERs), as well as cost-
effectiveness scatterplots and acceptability curves. Version 9.0 is the
most recent release of the CDM and was used for all analyses, with
the UKPDS 68 risk equations applied for prediction of risk of cardio-
vascular complications.26 Base case and sensitivity analyses were per-
formed using a first-order Monte Carlo approach, with probabilistic
sensitivity analysis (PSA) performed separately using a second-order
Monte Carlo approach. Clinical and cost outcomes were discounted at
3.5% per annum, as per NICE guidelines.27 Outcomes were projected
over patient lifetimes, in line with guidance on the assessment of
cost-effectiveness of interventions for diabetes.27,28 The model takes
into account mortality as a result of diabetes-related complications
and background mortality based on UK-specific life tables.29
2.2 | Baseline cohort characteristics and initial
treatment effects
Baseline cohort characteristics for the modelling analysis were taken
from the SUSTAIN 7 study.20 The mean (standard deviation [SD]) age
of the cohort was 56 (10.6) years, with a mean duration of T2DM of
7.4 (5.7) years, mean HbA1c of 8.2 (0.9)% (66.1 [10.1] mmol/mol), and
mean BMI of 33.5 (6.8) kg/m2. Alcohol and tobacco consumption
were assumed to be the same as that of the general UK population, as
these data were not collected in the SUSTAIN 7 study.30,31 Changes
in physiological parameters with once-weekly semaglutide and dula-
glutide were based on mean changes from baseline at 40 weeks in the
SUSTAIN 7 study, with hypoglycaemic events assessed across the
duration of the trial (Table 1).20 Both statistically and non-statistically
significant differences between the treatment arms were included.
Pre-specified statistical analyses assessed the statistical significance
of differences in treatment effects between once-weekly semaglutide
1 mg and dulaglutide 1.5 mg, but post-hoc analyses were required to
determine the statistical significance of differences in treatment
effects between once-weekly semaglutide 0.5 mg and dulaglutide
1.5 mg. Data were taken from pre-specified endpoints wherever pos-
sible, but in order to fulfil all data requirements for an analysis using
the CDM, a number of analyses of post-hoc endpoints were required,
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including serum lipids and hypoglycaemic events, to ensure that defi-
nitions met those used in the IQVIA CORE Diabetes Model.
2.3 | Treatment switching and long-term parameter
progression
A simple treatment algorithm which assumed that patients received
once-weekly semaglutide or dulaglutide for 3 years was employed, as
per previous long-term cost-effectiveness analyses of GLP-1 receptor
agonists submitted to NICE and published in peer-reviewed
journals.32–35 This is also supported by data from general practice in
the European Union big five markets, which reported a mean duration
of treatment with GLP-1 receptor agonists of 29.35 months, rounded
to 3 years, as treatment switching can occur only at the end of an
annual cycle in the CDM.36 After 3 years, treatment with once-weekly
semaglutide or dulaglutide was discontinued and patients were
assumed to intensify to basal insulin therapy with the most commonly
used basal insulin analogue available in the UK, insulin glargine, with
the cost of the least expensive, biosimilar version of insulin glargine
applied (Abasaglar). Patients continued this treatment for the remain-
der of their lifetimes. It should be noted that further treatment switch-
ing, such as switching to basal-bolus insulin, would not have affected
the differences in clinical outcomes and the costs between treatment
arms, provided that it occurred at the same time point. Hypoglycaemic
events following intensification were modelled based on the UK
Hypoglycaemia Study Group and were equal in all treatment arms.37
After applying the treatment effects in the first year of the analy-
sis, benefits in terms of HbA1c and BMI were assumed to persist for
the 3 years during which patients received GLP-1 receptor agonist
treatment, with differences abolished upon treatment intensification.
Upon intensification, HbA1c was brought to 7% (53 mmol/mol) in all
treatment arms, based on guidelines released by NICE (although a
patient-centred approach may result in modification of this goal).6
HbA1c remained equal in all treatment arms for the remainder of the
analysis. BMI returned to baseline following intensification. Therefore,
no differences in HbA1c and BMI were seen following treatment
intensification and, while clinical practice may vary among patients in
the UK, this resulted in a balanced cost-effectiveness analysis, with
differences maintained only while there were differences in costs.
Alternative treatment-switching and parameter-progression assump-
tions were explored in sensitivity analyses.
2.4 | Costs and utilities
Costs were accounted from the perspective of a UK healthcare payer,
with all costs expressed in 2016 pounds sterling (GBP). Unit costs of
T2DM medications were taken from the Monthly Index of Medical
Specialities (MIMS) database and were used to calculate annual treat-
ment costs, with resource use based on the SUSTAIN 7 trial.20,38
Annual costs of treatment with once-weekly semaglutide and dulaglu-
tide were equivalent. Following intensification after 3 years, patients
were assumed to receive 40 IU of basal insulin, based on the defined
daily dose.
Costs associated with treatment of diabetes-related complica-
tions were sourced from a systematic literature review, conducted in
2017, which identified UK-specific costs from published sources.39–50
Costs were inflated to 2016 values where necessary, using the Health
and Community Health Services Index (Appendix S1).51
TABLE 1 Treatment effects and adverse event rates
Parameter
Mean (standard error)
Once-weekly semaglutide 0.5 mg Once-weekly semaglutide 1 mg Dulaglutide 1.5 mg
Physiological parameters (applied in the first year of the analysis)
HbA1c (%) −1.5 (0.06) −1.8 (0.06)* −1.4 (0.06)
HbA1c (mmol/mol) −16.5 (0.6)) −19.4 (0.6)* −14.9 (0.6)
Systolic blood pressure (mmHg) −2.4 (0.8) −4.9 (0.8) −2.9 (0.8)
Diastolic blood pressure (mmHg) −0.6 (0.5) −2.0 (0.5)* 0.0 (0.5)
Total cholesterol (mg/dL) −7.0 (1.7) −5.2 (1.8) −2.6 (1.8)
HDL cholesterol (mg/dL) −0.5 (0.3)* 0.7 (0.4) 0.8 (0.4)
LDL cholesterol (mg/dL) −3.1 (1.5) −0.2 (1.6) 0.7 (1.5)
Triglycerides (mg/dL) −14.3 (3.1) −21.8 (2.9) −16.5 (3.0)
BMI (kg/m2) −1.6 (0.1)* −2.3 (0.1)* −1.1 (0.1)
Estimated glomerular filtration rate (mL/min/1.73 m2) −2.5 (0.6) −2.7 (0.6) −3.8 (0.5)
Adverse event rates (applied in the first 3 years of the analysis)
Non-severe hypoglycaemia event rate (events per
100 patient years)
1.3 2.6 1.3
Severe hypoglycaemia event rate (events per
100 patient years)
0.00 0.4 0.8
Proportion of non-severe hypoglycaemic events that
are nocturnal
0.00 0.00 0.00
Proportion of severe hypoglycaemic events that are
nocturnal
0.00 0.00 0.00
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Statistically significant difference at 95% confidence level vs dulaglutide 1.5 mg. Lipid values are presented in mg/dL, as these are required by the IQVIA
CORE Diabetes Model. Total cholesterol, HDL cholesterol and LDL cholesterol values can be converted from mg/dL to mmol/L by multiplying by 38.67.
Triglyceride values can be converted from mg/dL to mmol/L by multiplying by 88.5.
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Utilities were taken from a 2014 review by Beaudet et al, with
the cost of hypoglycaemia disutilities coming from Evans et al 2013,
published after the literature searches by Beaudet et al had been com-
pleted.52,53 Beaudet et al reviewed the methods of identified publica-
tions to ensure that they met the criteria of the NICE reference case.
Values used in the present analysis are shown in Appendix S1.
Quality-adjusted life expectancy was assessed using the CORE
Default Method, which involves taking the lowest state utility associ-
ated with existing complications and adding event disutilities for any
events that occur during that year to create annual utility scores for
each simulated patient.
2.5 | Identifying key drivers of clinical outcomes
To identify the key drivers of outcomes with once-weekly semaglutide
0.5 and 1 mg compared with dulaglutide 1.5 mg, a series of five simu-
lations were run for each comparison. In each analysis, only the differ-
ence in one of the following was applied in the once-weekly
semaglutide arm: HbA1c, blood pressure (systolic and diastolic), serum
lipids, BMI and hypoglycaemic event rates. All other parameters were
equal to the dulaglutide 1.5 mg arm, allowing assessment of the rela-
tive impact of each aspect on long-term outcomes.
2.6 | Sensitivity analyses
A series of sensitivity analyses were performed to assess the robust-
ness of the base case findings. An analysis was performed with only
the statistically significant differences in treatment effects applied in
the once-weekly semaglutide arms: high-density lipoprotein (HDL)
cholesterol and BMI in the once-weekly semaglutide 0.5 mg compari-
son, HbA1c, diastolic blood pressure and BMI in the once-weekly
semaglutide 1 mg comparison (Table 1). Simulations were run with
time horizons of 10, 25 and 35 years. It should be noted that a time
horizon of 50 years was required for all modelled patients to have
died; therefore, shorter time horizons do not capture all complications
and costs. Simulations were performed with discount rates of 0% and
6%. Treatment effects were applied in an alternative cohort, with
baseline data taken from the NICE THIN cohort (Appendix S1), cho-
sen, as in the development of the NICE T2DM treatment guidelines
(NG28), to reflect a typical cohort of individuals with T2DM in
the UK.54
Alternative parameter progressions and treatment effects were
assessed in a series of analyses. Base case analyses assumed that the
BMI benefit associated with once-weekly semaglutide was abolished
upon treatment switching so an alternative was explored, with BMI
differences maintained for the duration of the simulation. In a sepa-
rate analysis, the UKPDS HbA1c progression equation was applied in
all arms from initiation of the simulation, resulting in an increase in
HbA1c over time, with the differences between arms gradually
reduced. Simulations were also performed, applying the upper and
lower limits of the 95% confidence intervals of the estimated treat-
ment differences in HbA1c and BMI.
Simulations were performed with the year of treatment switching
brought forward to the end of year 2 and pushed back to the end of
year 5. An additional scenario was prepared, applying the UKPDS
HbA1c progression equation and with treatment switching occurring
when HbA1c exceeded 7.5% (58 mmol/mol), the threshold for treat-
ment intensification according to the NICE guidelines.6 The impact of
alternative insulin costs following intensification was explored by
applying the cost of neutral protamine Hagedorn (NPH) insulin. The
effect of over- or underestimating the direct cost of treating diabetes-
related complications was investigated in two scenarios, with costs
increased and decreased by 10%.
An update to the CDM, incorporating data from the UKPDS
82, has been released and an analysis using these risk equations to
predict cardiovascular events was run. Whilst a validation study of
the revised model has been published, the proprietors of the model
suggest that the update is used in a sensitivity analysis, with the
previous version being used in the base case.25 Alternative utilities
relating to BMI and hypoglycaemic events were applied to two
scenarios, applying a BMI disutility from Lee et al and disutilities
relating to hypoglycaemic events from Currie et al (Appendix S1).55
PSA was performed using the predefined function in the CDM.
Cohort characteristics, treatment effects, and complication costs and
utilities were sampled from distributions and the simulation was car-
ried out using a second-order Monte Carlo approach. Sampling
around model inputs allows the uncertainty around these inputs to
be captured and the confidence in the model outputs to be assessed.
3 | RESULTS
3.1 | Base case analysis
Projections of long-term clinical outcomes in individuals with T2DM
in the UK who were not achieving glycaemic control with metformin
indicated that once-weekly semaglutide 0.5 and 1 mg were associated
with improvements in discounted life expectancy of 0.04 and
0.10 years, respectively, and discounted quality-adjusted life expec-
tancy of 0.04 and 0.10 QALYs, respectively, compared with dulaglu-
tide 1.5 mg, with all differences found to be statistically significant
(Table 2). Improved clinical outcomes were the result of reduced
cumulative incidence and delayed time to onset of diabetes-related
complications over patient lifetimes, with benefits observed across all
micro- and macrovascular complications included in the analysis
(Appendix S1).
Once-weekly semaglutide 0.5 and 1 mg were associated with
overall cost savings of GBP 35 (not statistically significant) and GBP
106 (statistically significant), respectively, vs dulaglutide 1.5 mg over a
patient's lifetime (Table 2). Differences between the treatment arms
are relatively small, as differences in HbA1c and BMI were assumed
to be maintained for only 3 years in the modelling analysis. Both doses
of once-weekly semaglutide were associated with small increases in
treatment costs because of increased survival, despite equivalent
treatment costs with once-weekly semaglutide and dulaglutide. How-
ever, this was entirely offset by the reduced costs associated with
diabetes-related complications, most notably, ophthalmic and cardio-
vascular complications, with once-weekly semaglutide 0.5 mg (both
resulting in cost savings of GBP 17) and avoided cardiovascular
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complications with once-weekly 1 mg (resulting in cost savings of
GBP 96).
Projection of long-term outcomes indicated that both life
expectancy and quality-adjusted life expectancy were improved with
once-weekly semaglutide 0.5 and 1 mg treatment compared with
dulaglutide 1.5 mg, at a reduced cost from a healthcare payer perspec-
tive. Therefore, once-weekly semaglutide 0.5 and 1 mg were consid-
ered dominant vs dulaglutide 1.5 mg for treatment of individuals with
T2DM in the UK who were not achieving glycaemic control with
metformin.
3.2 | Key drivers of clinical outcomes
Testing for the key drivers of quality-adjusted life expectancy bene-
fits showed differences between the two once-weekly semaglutide
doses (Table 3). With once-weekly semaglutide 0.5 mg, the greater
HbA1c reduction vs dulaglutide (−1.5% vs −1.4% [16.5 vs
14.9 mmol/mol]) was the biggest contributor to improved clinical
outcomes. In the comparison of once-weekly semaglutide 1 mg vs
dulaglutide, the greater BMI reduction (−2.33 kg/m2 vs −1.08
kg/m2) was the biggest contributor to improved clinical outcomes,
followed by the greater reductions in HbA1c (−1.8% vs −1.4% [19.4
vs 14.9 mmol/mol]) and blood pressure (systolic blood pressure,
−4.9 mm Hg vs −2.9 mm Hg and diastolic blood pressure, −2.1 mm
Hg vs 0.0 mmHg).
3.3 | Sensitivity analyses
Sensitivity analyses showed that the base case results were robust to
changes in the input parameters and assumptions used, with both
doses of once-weekly semaglutide remaining dominant in all except
one scenario each (Table 4). Including only the statistically significant
differences between semaglutide 0.5 mg and dulaglutide 1.5 mg led to
decreased clinical benefits and increased incremental costs, yielding
an ICER of GBP 18446 per QALY gained. The only differences
between treatment arms in this scenario were in BMI and HDL cho-
lesterol; as such, the greater reduction in HbA1c with once-weekly
semaglutide 0.5 mg, the key driver of improved clinical outcomes, was
no longer applied.
When the UKPDS HbA1c progression equation was applied
with treatment switching when HbA1c exceeded 7.5% (58 mmol/
mol), once-weekly semaglutide 1 mg was associated with greater
clinical benefits but increased costs vs dulaglutide 1.5 mg, result-
ing in an ICER of GBP 1135 per QALY gained. This was the result
of asymmetric timing of treatment switching in the two treatment
arms. Patients received once-weekly semaglutide 1 mg for
4 years, while patients received dulaglutide 1.5 mg for only
3 years and received the less costly insulin abasaglar during the
fourth year of analysis.
While the magnitude of clinical benefits and cost savings varied,
once-weekly semaglutide 0.5 and 1 mg were considered dominant vs
dulaglutide 1.5 mg in all other analyses.
PSA showed mean results similar to those of the base case, but
increased measures of variance around the mean outcomes, with both
doses of once-weekly semaglutide remaining dominant. Based on this
analysis, assuming a willingness-to-pay threshold of GBP 20 000 per
QALY gained, the probabilities of once-weekly semaglutide 0.5 and
1 mg being cost-effective vs dulaglutide 1.5 mg were 57.2% and
77.8%, respectively. A cost-effectiveness acceptability curve is shown
in Figure 1, and the cost-effectiveness scatterplot is shown in
Appendix S1.
TABLE 2 Long-term cost-effectiveness outcomes in the base case
analysis
Health outcomes
Once-weekly
semaglutide
0.5 mg
Dulaglutide
1.5 mg
Difference
Discounted life
expectancy
(years)
13.64 (0.18) 13.60 (0.18) +0.04 (+0.02 to
+0.05)
Discounted
quality-adjusted
life expectancy
(QALYs)
9.00 (0.12) 8.96 (0.12) +0.04 (+0.03 to
+0.05)
Discounted direct
costs (GBP)
21 659 (562) 21 693 (538) −35 (−81 to
+12)
ICER (GBP per
QALY gained)
Once-weekly semaglutide dominant
Health outcomes
Once-weekly
semaglutide
1 mg
Dulaglutide
1.5 mg
Difference
Discounted life
expectancy
(years)
13.70 (0.19) 13.60 (0.18) +0.10 (+0.08 to
+0.11)
Discounted
quality-adjusted
life expectancy
(QALYs)
9.06 (0.13) 8.96 (0.12) +0.10 (+0.09 to
+0.11)
Discounted direct
costs (GBP)
21 588 (557) 21 693 (538) −106 (−151 to
−60)
ICER (GBP per
QALY gained)
Once-weekly semaglutide dominant
Abbreviations: GBP, 2016 pounds sterling; ICER, incremental
cost-effectiveness ratio; QALYs, quality-adjusted life years. Values are
means (standard deviation) for outcomes in each arm and mean (95% con-
fidence interval) for differences. Life expectancy and quality-adjusted life
expectancy outcomes are rounded to two decimal places.
TABLE 3 Key drivers of clinical differences between once-weekly
semaglutide and dulaglutide
Difference in quality-adjusted life expectancy
(QALYs)
Analysis
Once-weekly
semaglutide 0.5 mg
versus dulaglutide
1.5 mg
Once-weekly
semaglutide 1 mg
versus dulaglutide
1.5 mg
Base case analysis +0.04 +0.10
HbA1c difference
only
+0.02 +0.02
Blood pressure
difference only
0.00 +0.02
Lipid difference only 0.00 0.00
BMI difference only +0.01 +0.03
Hypoglycaemia
difference only
0.00 0.00
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin;
QALY, quality-adjusted life year. Quality-adjusted life expectancy out-
comes are rounded to two decimal places.
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TABLE 4 Sensitivity analysis results
Analysis
Discounted quality-adjusted life expectancy
(QALYs) Discounted direct costs (GBP)
ICER (GBP
per QALY gained)
Once-weekly
semaglutide
1 mg
Dulaglutide
1.5 mg Difference
Once-weekly
semaglutide
1 mg
Dulaglutide
1.5 mg Difference
Base case 9.06 8.96 +0.10 21 588 21 693 −106 Once-weekly
semaglutide
dominant
Statistically significant
differences only
9.03 8.96 +0.07 21 642 21 693 −52 Once-weekly
semaglutide
dominant
35-year time horizon 9.01 8.92 +0.08 21 266 21 467 −201 Once-weekly
semaglutide
dominant
20-year time horizon 7.81 7.74 +0.07 16 957 17 136 −179 Once-weekly
semaglutide
dominant
10-year time horizon 5.17 5.13 +0.04 10 167 10 287 −120 Once-weekly
semaglutide
dominant
0% discount rates 13.69 13.53 +0.16 35 436 35 564 −128 Once-weekly
semaglutide
dominant
6% discount rates 7.13 7.05 +0.08 16 238 16 329 −90 Once-weekly
semaglutide
dominant
NICE (THIN) baseline
cohort data
8.86 8.78 +0.08 19 261 19 471 −210 Once-weekly
semaglutide
dominant
BMI difference maintained
for patient lifetimes
9.15 8.96 +0.19 21 586 21 693 −107 Once-weekly
semaglutide
dominant
UKPDS HbA1c creep for
duration of the analysis
(no change upon
treatment intensification)
8.57 8.47 +0.11 24 517 24 722 −205 Once-weekly
semaglutide
dominant
Upper 95% CI of HbA1c
estimated treatment
difference
9.06 8.96 +0.10 21 498 21 693 −196 Once-weekly
semaglutide
dominant
Lower 95% CI of HbA1c
estimated treatment
difference
9.03 8.96 +0.07 21 614 21 693 −79 Once-weekly
semaglutide
dominant
Upper 95% CI of BMI
estimated treatment
difference
9.06 8.96 +0.10 21 537 21 693 −156 Once-weekly
semaglutide
dominant
Lower 95% CI of BMI
estimated treatment
difference
9.05 8.96 +0.09 21 604 21 693 −89 Once-weekly
semaglutide
dominant
Treatment switching at
2 years
8.99 8.93 +0.06 21 220 21 360 −140 Once-weekly
semaglutide
dominant
Treatment switching at
5 years
9.14 9.02 +0.12 22 112 22 377 −265 Once-weekly
semaglutide
dominant
Treatment switching at
7.5% (58 mmol/mol)
HbA1c threshold (using
UKPDS progression)
8.60 8.47 +0.13 24 874 24 722 +152 1135
NPH basal insulin cost upon
treatment intensification
9.06 8.96 +0.10 20 205 20 322 −117 Once-weekly
semaglutide
dominant
Cost of complications +10% 9.06 8.96 +0.10 22 761 22 883 −122 Once-weekly
semaglutide
dominant
Cost of complications
−10%
9.06 8.96 +0.10 20 408 20 497 −89 Once-weekly
semaglutide
dominant
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TABLE 4 (Continued)
Analysis
Discounted quality-adjusted life expectancy
(QALYs) Discounted direct costs (GBP)
ICER (GBP
per QALY gained)
Once-weekly
semaglutide
1 mg
Dulaglutide
1.5 mg Difference
Once-weekly
semaglutide
1 mg
Dulaglutide
1.5 mg Difference
UKPDS 82 risk equations
applied
9.35 9.31 +0.04 22 160 22 338 −178 Once-weekly
semaglutide
dominant
Lee et al BMI disutility
applied
8.61 8.50 +0.11 21 588 21 693 −106 Once-weekly
semaglutide
dominant
Currie et al hypoglycaemia
disutilities
9.18 9.09 +0.10 21 588 21 693 −106 Once-weekly
semaglutide
dominant
Analysis
Discounted quality-adjusted life expectancy
(QALYs) Discounted direct costs (GBP)
ICER (GBP per
QALY gained)
Once-weekly
semaglutide
0.5 mg
Dulaglutide
1.5 mg Difference
Once-weekly
semaglutide
0.5 mg
Dulaglutide
1.5 mg Difference
Base case 9.00 8.96 +0.04 21 659 21 693 −35 Once-weekly
semaglutide
dominant
Statistically significant
differences only
8.97 8.96 +0.01 21 824 21 693 +131 18 446
35-year time horizon 8.94 8.92 +0.01 21 384 21 467 −83 Once-weekly
semaglutide
dominant
20-year time horizon 7.76 7.74 +0.01 17 052 17 136 −84 Once-weekly
semaglutide
dominant
10-year time horizon 5.15 5.13 +0.02 10 235 10 287 −51 Once-weekly
semaglutide
dominant
0% discount rates 13.58 13.53 +0.06 35 512 35 564 −52 Once-weekly
semaglutide
dominant
6% discount rates 7.08 7.05 +0.03 16 301 16 329 −28 Once-weekly
semaglutide
dominant
NICE (THIN) baseline
cohort data
8.81 8.78 +0.02 19 463 19 471 −8 Once-weekly
semaglutide
dominant
BMI difference maintained
for patient lifetimes
9.03 8.96 +0.07 21 671 21 693 −23 Once-weekly
semaglutide
dominant
UKPDS HbA1c creep for
duration of the analysis
(no change upon
treatment
intensification)
8.50 8.47 +0.03 24 643 24 722 −78 Once-weekly
semaglutide
dominant
Upper 95% CI of HbA1c
estimated treatment
difference
9.00 8.96 +0.04 21 599 21 693 −94 Once-weekly
semaglutide
dominant
Lower 95% CI of HbA1c
estimated treatment
difference
8.97 8.96 +0.01 21 671 21 693 −23 Once-weekly
semaglutide
dominant
Upper 95% CI of BMI
estimated treatment
difference
9.00 8.96 +0.04 21 683 21 693 −10 Once-weekly
semaglutide
dominant
Lower 95% CI of BMI
estimated treatment
difference
8.98 8.96 +0.02 21 679 21 693 −14 Once-weekly
semaglutide
dominant
Treatment switching at
2 years
8.94 8.93 +0.01 21 324 21 360 −36 Once-weekly
semaglutide
dominant
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4 | DISCUSSION
Once-weekly semaglutide 0.5 and 1 mg were found to be dominant
over dulaglutide 1.5 mg based on the SUSTAIN 7 trial, improving clini-
cal outcomes and reducing direct costs in individuals with T2DM.
Greater reductions in HbA1c and BMI were the key drivers of
improved long-term outcomes. Once-weekly semaglutide was associ-
ated with increased treatment costs compared with dulaglutide,
despite equal acquisition costs, because of the increase in survival
resulting from improved outcomes. However, cost savings resulting
from the avoided diabetes-related complications entirely offset this
increase. While overall cost savings per patient were small, these were
found to be statistically significant for the higher dose of once-weekly
semaglutide. These small cost savings at a per patient level would
translate to a substantially larger amount when extrapolated over a
national patient population with type 2 diabetes using once-weekly
GLP-1 receptor agonist therapy.
Achievement of treatment goals and tolerability can affect adher-
ence, which may impact cost-effectiveness. In the SUSTAIN 7 clinical
trial, once-weekly semaglutide 0.5 mg was associated with propor-
tions of patients achieving glycaemic control targets similar to those
associated with dulaglutide 1.5 mg, while once-weekly semaglutide
was associated with a significantly greater proportion of patients
achieving HbA1c targets.20 Discontinuation rates were slightly higher
with once-weekly semaglutide 0.5 mg (16%) and 1 mg (17%) com-
pared with dulaglutide 1.5 mg (12%).20 The percentages of patients
experiencing adverse events, adverse events that led to premature
treatment discontinuation, and gastrointestinal adverse events were
similar with once-weekly semaglutide 0.5 mg, once-weekly semaglu-
tide 1 mg and dulaglutide 1.5 mg. Further studies are required to
determine how the outcomes identified in randomized, controlled tri-
als translate to clinical practice.
There is increasing interest in the impact of medications for
T2DM on cardiovascular risk, in addition to their impact on
TABLE 4 (Continued)
Analysis
Discounted quality-adjusted life expectancy
(QALYs) Discounted direct costs (GBP)
ICER (GBP per
QALY gained)
Once-weekly
semaglutide
0.5 mg
Dulaglutide
1.5 mg Difference
Once-weekly
semaglutide
0.5 mg
Dulaglutide
1.5 mg Difference
Treatment switching at
5 years
9.04 9.02 +0.02 22 212 22 377 −165 Once-weekly
semaglutide
dominant
Treatment switching at
7.5% (58 mmol/mol)
HbA1c threshold (using
UKPDS progression)
8.50 8.47 +0.03 24 643 24 722 −78 Once-weekly
semaglutide
dominant
NPH basal insulin cost
upon treatment
intensification
9.00 8.96 +0.04 20 283 20 322 −39 Once-weekly
semaglutide
dominant
Cost of complications
+10%
9.00 8.96 +0.04 22 843 22 883 −41 Once-weekly
semaglutide
dominant
Cost of complications
−10%
9.00 8.96 +0.04 20 468 20 497 −29 Once-weekly
semaglutide
dominant
UKPDS 82 risk equations
applied
9.33 9.31 +0.02 22 252 22 338 −86 Once-weekly
semaglutide
dominant
Lee et al BMI disutility
applied
8.55 8.50 +0.04 21 659 21 693 −35 Once-weekly
semaglutide
dominant
Currie et al hypoglycaemia
disutilities
9.12 9.09 +0.04 21 659 21 693 −35 Once-weekly
semaglutide
dominant
Abbreviations: BMI, body mass index; CI, confidence interval; GBP, 2016 pounds sterling; HbA1c, glycated haemoglobin; NPH, neutral protamine Hage-
dorn; QALY, quality-adjusted life year. Quality-adjusted life expectancy outcomes are rounded to two decimal places.
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conventional risk factors for cardiovascular events. Once-weekly
semaglutide demonstrated cardiovascular benefits in the SUSTAIN
6 trial (NCT01720446). Once-weekly semaglutide was associated
with a significantly lower risk of cardiovascular death, non-fatal
myocardial infarction and non-fatal stroke compared with placebo
plus standard of care.56 The REWIND study (NCT01394952) to
assess the impact of dulaglutide on cardiovascular risk has not yet
been reported. Until data from the REWIND study are available, it is
not possible to include further information concerning differential
impact on cardiovascular risk with once-weekly semaglutide and
dulaglutide.
NICE guidelines currently recommend GLP-1 receptor agonists as
part of triple therapy for individuals with T2DM and a BMI over
35 kg/m2, those for whom insulin therapy would have significant
occupational implications and those for whom weight loss would ben-
efit other significant obesity-related comorbidities.6 This is not in
agreement with the present analysis in which dual therapy following
metformin failure was considered. However, the joint guidelines
released by the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD) recommend
the use of GLP-1 receptor agonists as a second-line treatment option.
The draft update to ADA/EASD consensus guidelines states that
GLP-1 receptor agonists are a preferred second-line treatment if
weight gain is a concern, and that interventions with a proven cardio-
vascular benefit are preferred (new guidelines are due to be released
following the 54th EASD Annual Meeting 2018 in Berlin, Ger-
many).13,57 Other second-line options for individuals with T2DM
include DPP-4 inhibitors, SGLT-2 inhibitors and basal insulin.6 In the
SUSTAIN 2 trial, both doses of once-weekly semaglutide were associ-
ated with significantly larger reductions in HbA1c, systolic blood pres-
sure and BMI vs the DPP-4 inhibitor sitagliptin.58 There are currently
no head-to-head clinical trials comparing once-weekly semaglutide
with SGLT-2 inhibitors, but an NMA suggests that both doses of
once-weekly semaglutide are associated with greater reductions in
HbA1c, that once-weekly semaglutide 1 mg is associated with greater
reductions in body weight, and that once-weekly semaglutide 0.5 mg
is associated with weight loss similar to that with SGLT-2 inhibitors.14
The SUSTAIN 8 trial (NCT03136484) will provide a head-to-head
comparison of once-weekly semaglutide with SGLT-2 inhibitors (cana-
gliflozin 300 mg). As well as in the SUSTAIN 7 trial (NCT02648204),
once-weekly semaglutide was compared with other GLP-1 receptor
agonists in the SUSTAIN 3 trial (exenatide extended-release,
NCT01885208) and in an NMA (liraglutide, dulaglutide, exenatide
twice-daily, exenatide extended-release, lixisenatide and albiglutide) in
which once-weekly semaglutide was associated with greater reduc-
tions in HbA1c and body weight in all comparisons.19,21 Once-weekly
semaglutide was compared with basal insulin in the SUSTAIN 4 trial
(NCT02128932) and was associated with significant improvements in
HbA1c and body weight.59 Additionally, sub-group analyses based on
baseline HbA1c and BMI have shown that once-weekly semaglutide is
consistently more efficacious than other treatment options included
in the SUSTAIN trial programme in all sub-groups, rather than simply
in groups with a high BMI at baseline.22,60,61 As once-weekly semaglu-
tide has been shown to be more efficacious than a number of treat-
ment options for individuals with T2DM, further analyses are required
to assess its cost-effectiveness at each stage of the T2DM treatment
algorithm, to elucidate the optimal place for once-weekly semaglutide
and to maximize value for money within the NHS.
A limitation of this study was the reliance on short-term clinical
trial data to make long-term projections. However, this remains one of
the essential tenets of health economic modelling and it is arguably
one of the best available options to inform decision making in the
absence of long-term data. Moreover, projecting outcomes over
patient lifetimes is recommended in guidelines for economic evalua-
tion of interventions for T2DM.28 Whilst there is always an element
of clinical doubt concerning the accuracy of such an approach, every
effort was made in the present analysis to minimize this doubt, pri-
marily by using a model of diabetes that has been extensively pub-
lished and validated, in addition to extensive sensitivity analyses.24,25
The aim of health economic analyses, such as the present study, is to
inform and to reduce uncertainty concerning decision making when
long-term data are lacking.
A further limitation of the present analysis is that the model does
not reflect personalization of treatment. EASD and ADA guidelines
indicate that patients should be routinely assessed and their therapy
should be modified and their treatment goals revised accordingly.13,58
The 3-year treatment switch presented in this analysis could therefore
be subject to criticism. The modelling analysis also did not include
addition of basal insulin with continuation of GLP-1 receptor agonists.
This approach is recommended in treatment guidelines, but all studies
have assessed addition of a GLP-1 receptor agonist to a basal insulin
regimen rather than addition of basal insulin to a GLP-1 receptor ago-
nist regime.13,58 Therefore, changes in risk factors upon addition of
basal insulin to once-weekly semaglutide and dulaglutide would be
associated with significant uncertainty. Despite these limitations, the
present study offers a clear and simple direct comparison of the two
interventions, aiming to assess the cost-effectiveness of once-weekly
semaglutide and dulaglutide in the UK.
In conclusion, once-weekly semaglutide represents a cost-
effective option for treating individuals with T2DM in the UK who are
not achieving glycaemic control with metformin and it is projected to
both improve quality-adjusted life expectancy and reduce costs com-
pared with treatment with dulaglutide.
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